After consultation with the infectious diseases team, he started a hepatoprotective anti-tubercular regimen (moxifloxacin, ethambutol, amikacin, and linezolid with pyridoxine) due to significant baseline hepatocellular injury (alanine aminotransferase peaking at 465 U/L), resulting in significant clinical and biochemical improvement. At three- and six-month follow-up, liver function tests normalized, and repeat imaging showed near-complete resolution of lymphadenopathy with no residual biliary dilatation. He was discharged on therapy with close outpatient follow-up. This evidence concerns the gene GPT and infectious disease.